p53 and MDM2: Antagonists or Partners in Crime?

Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Cancer cell (Impact Factor: 23.52). 04/2009; 15(3):161-2. DOI: 10.1016/j.ccr.2009.02.004
Source: PubMed


Therapeutics that disrupt the p53-MDM2 interaction show promise for cancer treatment but surprisingly have different biological outcomes. A study by Enge et al. in this issue of Cancer Cell shows that the ability of MDM2 to target hnRNP K for degradation contributes to the decision to induce apoptosis rather than cell-cycle arrest.

Full-text preview

Available from:
  • Source
    • "MDM2, mdm2 TP53 binding protein homologue; RB, retinoblastoma. pathway in early cancer development (Eischen and Lozano 2009; Hede et al. 2011). CDKN1A gene is located on chromosome 6p. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumors of brain tissue and meninges create a heterogeneous group with various biological behavior, therapy management and differing prognosis. Some of these do not require treatment, some can be cured by surgery and some are rapidly fatal despite treatment. Despite huge progress in tumor research, innovations in diagnostic tools and therapy, prognosis remains, in case of malignant tumor types, very serious. There has been an increased understanding of molecular abnormalities occurring in primary brain tumors. Genome-wide analyses of tumors have improved the knowledge in tumor biology. The aim of the research is to explain the oncogenesis features thus leading to the use of new therapeutic modalities in order to prolong survival rate of patients and at the same time providing satisfactory life quality. This article offers a short review of the basic genetic alterations present with some histological types of brain tumors.
    Full-text · Article · Jun 2014 · General Physiology and Biophysics
  • Source
    • "The famous tumor suppressor gene TP53 is mutated in minimally half of all cancers. As a negative regulator of p53, mouse double minute 2 (MDM2) could bind to it with high affinity, leading to the reduction of p53 expression and functional inhibition; on the other hand, p53 enhances MDM2 transcription, which forms an important feedbackloop (Eischen et al., 2009). A polymorphism in MDM2 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: As a negative regulator of P53, MDM2 plays an important role in carcinogenesis; a polymorphism in its promoter region. SNP309 T>G, is known to increase the expression of MDM2, thus being considered related to higher susceptibility to neoplasia. However, no agreement has been achieved regarding its effects on gastric cancer. Methods: The present systematic meta-analysis was performed based on comprehensive literature search from Pubmed, Web of science and CBM databases. Results: It was suggested from 6 independent studies that the GG genotype is associated with a significantly increased risk of gastric cancer (Recessive: OR = 1.43, 95% CI = 1.08-1.91, P = 0.013), and subgroup analysis also confirmed the relationship (English publications-recessive model: OR = 1.45, 95% CI = 1.10-1.91, P = 0.009; Studies in China-recessive model: OR = 1.58, 95% CI = 1.08-2.30, P = 0.017). No publication bias was detected. Conclusion: The meta-analysis indicated a significant inverse association between GG genotype carriage and elevated risk of gastric cancer. However, more studies and detailed information are needed to fully address the topic.
    Full-text · Article · Mar 2013 · Asian Pacific journal of cancer prevention: APJCP
  • Source
    • "MDM2 inhibits p53 transcriptional activity, it acts as E3 ubiquitin ligase ubiquitinating and targeting p53 for proteasomal degradation, and it promotes the nuclear export of p53 (Figure 1). Vice versa, MDM2 is a p53 target gene illustrating how MDM2 and p53 form a tightly regulated negative feedback loop in which activated p53 upregulates MDM2 expression, which in turn will target p53 for degradation [3] [8] [9]. MDM2 deficiency leads to p53-driven, uncontrolled cell death already during embryonic development. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Murine double minute-2 (MDM2) is an intracellular molecule with multiple biologic functions. It serves as a negative regulator of p53 and thereby limits cell cycle arrest and apoptosis. Because MDM2 blockade suppresses tumor cell growth in vitro and in vivo, respective MDM2 inhibition is currently evaluated as anti-cancer therapy in clinical trials. However, the anti-proliferative effects of MDM2 inhibition also impair regenerative cell growth upon tissue injury. This was so far documented for tubular repair upon postischemic acute kidney injury and might apply to wound healing responses in general. Furthermore, MDM2 has numerous p53-independent effects. As a new entry, MDM2 was identified to act as a co-transcription factor for nuclear factor-kappa-light-enhancer of activated B cells (NF-κB) at cytokine promoters. This explains the potent anti-inflammatory effects of MDM2 inhibitors in vitro and in vivo. For example, the NF-κB-antagonistic and p53-agonistic activities of MDM2 inhibitors elicit potent therapeutic effects on experimental lymphoproliferative autoimmune disorders such as systemic lupus erythematosus. In this review, we discuss the classic p53-dependent, the recently discovered p53-independent, and the NF-κB-agonistic biologic functions of MDM2. We describe its complex regulatory role on p53 and NF-κB signaling and name areas of research that may help to foresee previously unexpected effects or potential alternative indications of therapeutic MDM2 blockade.
    Full-text · Article · Dec 2012 · Neoplasia (New York, N.Y.)
Show more